BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals (Nasdaq: BCRX) plans to present at the Jefferies Global Healthcare Conference in London on November 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCryst Pharmaceuticals (Nasdaq: BCRX) plans to present at the Jefferies Global Healthcare Conference in London on November 18, 2026. The presentation is scheduled for 8:30 a.m. ET. BioCryst also plans to present at the 9th Annual Evercore Healthcare Conference in Coral Gables, Florida, on December 1, 2026, at 8:45 a.m. ET. Live audio webcasts and replays will be accessible through the Investors & Media section of its website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
- 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 8:30 a.m. ET.
- 9th Annual Evercore Healthcare Conference in Coral Gables, FL, on Tuesday, December 1, 2026, at 8:45 a.m. ET.
Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
